Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The US Supreme Court has granted certiorari to hear a patent infringement case centered on the 'skinny label' strategy employed by generic drug manufacturers, involving Amarin Pharma. The case will address whether a generic drug maker can be held liable for inducing infringement when its product is labeled for non-pat…
Share This Article
Ready-to-post copy includes the article link.
Supreme Court Agrees to Review Amarin’s 'Skinny Label' Patent Dispute The US Supreme Court has granted certiorari to hear a patent infringement case centered on the 'skinny label' strategy employed by generic drug manufacturers, involving Amarin Pharma. The case will address whether a gen... Read the full IIPLA article: https://iipla.org/news/supreme-court-agrees-to-review-amarin-s-skinny-label-patent-dispute